Allergan Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Allergan Plc (AGN) from 2012 to 2016. Allergan generated a total of $14.6 billion revenues during 2016. Allergan reported a revenue growth of 14.8% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Allergan Revenues From 2012 To 2016

Here are the revenues and the revenue growth details of Allergan during the last five years:

  • Allergan generated a total of $5.9 billion revenues during 2012. Allergan reported a revenue growth of 29% year-over-year during 2012.
  • Allergan generated a total of $2.6 billion revenues during 2013. Allergan reported a revenue growth of -56% year-over-year during 2013.
  • Allergan generated a total of $4.7 billion revenues during 2014. Allergan reported a revenue growth of 79.7% year-over-year during 2014.
  • Allergan generated a total of $12.7 billion revenues during 2015. Allergan reported a revenue growth of 171.3% year-over-year during 2015.
  • Allergan generated a total of $14.6 billion revenues during 2016. Allergan reported a revenue growth of 14.8% year-over-year during 2016.

Why Analyze Revenue Growth?

Revenue growth is the most commonly analyzed financial metric. Revenue Growth is the percent increase (or decrease) of a company's revenue between two time periods. It is computed by using the following formula: ((revenues during the time period two - revenues during the time period one) / revenues during the time period one)*100. If the time periods are two consecutive years, then the revenue growth is referred to as the annual revenue growth year-over-year. If the time periods are two consecutive quarters, then the revenue growth is referred to as the quarterly revenue growth quarter-over-quarter. If the time periods refer to the same quarter in the two consecutive years, then the revenue growth is referred to as quarterly revenue growth year-over-year. In case the time periods are two non-consecutive years, then the revenue CAGR (Commutative Annual Growth Rate) is computed.

Revenue growth analysis is important for a number of reasons. First, it helps in understanding how a business is performing. If the revenue growth rates are positive, it means the business is performing well and the revenues are increasing. If the revenue growth rates are negative, it means the revenues are declining and the company needs to take measures to increase them. If they don't, the company will continue to shrink. Second, a company's historical revenue growth analysis along with the market size and market share analysis helps in forecasting the future revenues of a company. Third, a comparison of a company's growth rates with its competitors helps in determining who is winning more business. A revenue growth higher than the industry average translates into increasing market share. Companies with very high revenue growth rates have the potential to be the industry disrupters.

Allergan Ranking

With $14.6 billion revenues, Allergan ranked number 192 in the R&P Research list of top-3000 public companies in the US by revenues during 2016. Each one of the top-3000 companies generated more than $50 million of annual revenues during 2016.

The top-20 companies in the US by revenues during 2016 were:

  1. Walmart ($482.1 billion)
  2. ExxonMobil ($226.1 billion)
  3. Berkshire Hathaway ($223.6 billion)
  4. Apple ($215.6 billion)
  5. McKesson ($190.9 billion)
  6. UnitedHealth Group ($184.8 billion)
  7. CVS Health ($177.5 billion)
  8. General Motors ($166.4 billion)
  9. AT&T ($163.8 billion)
  10. Ford Motor ($151.8 billion)
  11. AmerisourceBergen ($146.8 billion)
  12. Amazon ($136 billion)
  13. Verizon ($126 billion)
  14. General Electric ($123.7 billion)
  15. Cardinal Health ($121.5 billion)
  16. Costco ($118.7 billion)
  17. Walgreens Boots Alliance ($117.4 billion)
  18. Chevron ($114.5 billion)
  19. Kroger ($109.8 billion)
  20. Express Scripts Holding ($100.3 billion)

For the purpose of performance benchmarking of a company with a sector or industry average, R&P Research associates every company with one sector and one industry. An industry consists of companies with related/similar business models. A sector comprises of a group of related/similar industries. For high-level analysis purposes, related/similar sectors are grouped into sector groups.

For example, Healthcare sector group is comprised of Life Sciences sector and Healthcare Services sector. Life Sciences sector is comprised of following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. Healthcare Services sector is comprised of following industries: Drug Stores, PBM and Distributors; Healthcare Payers; Healthcare Providers; Medical Software; Healthcare Research Services.

Allergan is associated with Healthcare Sector Group, Life Sciences Sector, and Pharmaceuticals Industry.

With $14.6 billion revenues, Allergan ranked number 30 of all the companies in the US Healthcare sector group. There were a total of 290 public companies in the US Healthcare sector group that had revenues greater than $50 million during 2016.

The top-10 companies in the US Healthcare sector group by revenues during 2016 were:

  1. McKesson ($190.9 billion)
  2. UnitedHealth Group ($184.8 billion)
  3. CVS Health ($177.5 billion)
  4. AmerisourceBergen ($146.8 billion)
  5. Cardinal Health ($121.5 billion)
  6. Walgreens Boots Alliance ($117.4 billion)
  7. Express Scripts Holding ($100.3 billion)
  8. Anthem ($84.9 billion)
  9. J&J ($71.9 billion)
  10. Aetna ($63.2 billion)

Healthcare sector group is comprised of the following sectors: Life Sciences; Healthcare Services.

With $14.6 billion revenues, Allergan ranked number 12 of all the companies in the US Life Sciences sector. There were a total of 197 public companies in the US Life Sciences sector that had revenues greater than $50 million during 2016.

The top-10 companies in the US Life Sciences sector by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Gilead Sciences ($30.4 billion)
  5. Medtronic ($28.8 billion)
  6. Abbvie ($25.6 billion)
  7. Amgen ($23 billion)
  8. Eli Lilly ($21.2 billion)
  9. Abbott Laboratories ($20.9 billion)
  10. Bristol Myers Squibb ($19.4 billion)

Life Sciences sector is comprised of the following industries: Pharmaceuticals; Medical Devices; Biotechnology; Diagnostics & Scientific Instruments. The definitions for each of the industries is as follows:

  • Pharmaceuticals industry includes companies that discover, develop, manufacture, and market medicines licensed for use as medications. In general these companies offer pharmaceutical products that can be described as prescription or over-the-counter medicines. Many Pharmaceutical companies also offer a diverse portfolio of animal health products, services and solutions. Many diversified pharmaceutical companies operate in more than two operating segments like consumer health products, medical devices and pharmaceutical.
  • Medical Devices industry includes manufacturers and distributors of medical equipments and medical supplies. Medical equipments include large scale capital equipmets such as X-Ray machines and MRI scanners and other nondisposable medical devices like stents and pacemakers. Medical supplies include makers of contact lenses, eyeglass lenses, bandages and other disposable products.
  • Biotechnology industry includes Biotechnology product companies, subscription companies, and service companies. Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from, or semi synthesized from biological sources. Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies.
  • Diagnostics & Scientific Instruments industry includes companies that provide testing products, diagnostic reagents, instruments and diagnostic services to aid in the detection and treatment of a wide range of diseases. It also includes molecular diagnostic and genetic testing companies that develop, manufacture, market and provide diagnostic tests, diagnostic systems and related products and services. Also included are companies that manufacture and market analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics.

With $14.6 billion revenues, Allergan ranked number 7 of all the companies in the US Pharmaceuticals industry. There were a total of 49 public companies in the US Pharmaceuticals industry that had revenues greater than $50 million during 2016.

The top-10 companies in the US Pharmaceuticals industry by revenues during 2016 were:

  1. J&J ($71.9 billion)
  2. Pfizer ($52.8 billion)
  3. Merck ($39.8 billion)
  4. Eli Lilly ($21.2 billion)
  5. Abbott Laboratories ($20.9 billion)
  6. Bristol Myers Squibb ($19.4 billion)
  7. Allergan ($14.6 billion)
  8. Shire ($11.4 billion)
  9. Mylan ($11.1 billion)
  10. Valeant Pharmaceuticals ($9.7 billion)

Companies Segmentation

To identify and analyze high/low growth or most/least profitable similar-size companies in different sectors or industries, R&P research classifies all companies into different segments based upon their revenues, revenue growth, and net profit margins.

Based upon their annual revenues, the companies are classified into one of the following four segments:

  1. Mega companies, having revenues greater than $50 billion.
  2. Very Large companies, having revenues between $10 billion and $50 billion.
  3. Large companies, having revenues between $1 billion and $10 billion.
  4. Mid-size companies, having revenues between $50 million and $1 billion.

With $14.6 billion revenues, Allergan was in the Very Large companies revenue segment during 2016. There were a total of 239 companies in the Very Large companies revenue segment during 2016.

Based upon their annual revenue growth, the companies are classified into one of the following eight segments:

  1. Very High positive growth companies, having annual revenue growth greater than 50%.
  2. High positive growth companies, having annual revenue growth between 20% and 50%.
  3. Medium positive growth companies, having annual revenue growth between 5% and 20%.
  4. Low positive growth companies, having annual revenue growth between 0% and 5%.
  5. Low negative growth companies, having annual revenue growth between -5% and 0%.
  6. Medium negative growth companies, having annual revenue growth between -20% and -5%.
  7. High negative growth companies, having annual revenue growth between -50% and -20%.
  8. Very High negative growth companies, having annual revenue growth less than -50%.

With 14.8% revenue growth year-over-year, Allergan was in the Medium positive revenue growth segment during 2016. There were a total of 876 companies in the Medium positive revenue growth segment during 2016. Of the US top-3000 companies, 1985 (nearly two-third of the total) had positive revenue growth and 1015 (nearly one-third of the total) had negative revenue growth during 2016.

Based upon their annual net profit margin, the companies are classified into one of the following eight segments:

  1. Very High positive margin companies, having net profit margin greater than 50%.
  2. High positive margin companies, having net profit margin between 20% and 50%.
  3. Medium positive margin companies, having net profit margin between 5% and 20%.
  4. Low positive margin companies, having net profit margin between 0% and 5%.
  5. Low negative margin companies, having net profit margin between -5% and 0%.
  6. Medium negative margin companies, having net profit margin between -20% and -5%.
  7. High negative margin companies, having net profit margin between -50% and -20%.
  8. Very High negative margin companies, having net profit margin less than -50%.

With a net margin of 102.8%, Allergan was in the Very High positive net profit margin segment during 2016. There were a total of 54 companies in the Very High positive net profit margin segment during 2016. Of the US top-3000 companies, 2244 (nearly three-fourth of the total) had positive net profit margin and 756 (nearly one-fourth of the total) had negative net profit margin during 2016.

Company Business Summary

Allergan plc, a specialty pharmaceutical company, develops, manufactures, markets, and distributes medical aesthetics, biosimilar, and over-the-counter pharmaceutical products worldwide. It operates through US Specialized Therapeutics, US General Medicine, and International segments. The company offers a portfolio of products that provide treatment for the central nervous system, gastroenterology, women's health and urology, ophthalmology, neurosciences, medical aesthetics, dermatology, plastic surgery, liver disease, inflammation, metabolic syndromes, and fibrosis, as well as Alzheimer's disease. It is also involved in developing ocular implants that reduce intraocular pressure associated with glaucoma; medical devices for the correction of prominent ears; and intranasal neurostimulation devices, as well as other dry eye products. In addition, the company distributes generic and branded pharmaceutical products primarily to independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics, and physician offices. Further, it develops a portfolio of breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. The company has licensing agreement with Assembly Biosciences, Inc.; Mimetogen Pharmaceuticals, Inc.; Almirall, S.A; Naurex, Inc.; and Merck & Co. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland.

Data Source

The chart and the data on this page are sourced from the R&P Research Industry Intelligence Platform. The platform provides the key financial metrics for all the public companies in the United States. The platform empowers users to compare last five or 15 years financial data of a company with the other companies or the industry averages. This benchmarking exercise yields powerful insights that can drive better business decisions.


Industry Peers and Competitors of Allergan

Eli Lilly (LLY) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Lilly Eli & Co with $21 billion revenues in the year 2016 was the number 4 Pharmaceuticals company. Read this report to know the top competitors of Eli Lilly and identify growth and cost optimization opportunities of Eli Lilly

Abbott Laboratories (ABT) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Abbott Laboratories with $21 billion revenues in the year 2016 was the number 5 Pharmaceuticals company. Read this report to know the top competitors of Abbott Laboratories and identify growth and cost optimization opportunities of Abbott Laboratories

Bristol Myers Squibb (BMY) Business Analysis – Analyze Historical Performance, Strategic...

Bristol Myers Squibb Co with $19 billion revenues in the year 2016 was the number 6 Pharmaceuticals company. Read this report to know the top competitors of Bristol Myers Squibb and identify growth and cost optimization opportunities of Bristol Myers Squibb

Shire (SHPG) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Shire Plc with $11 billion revenues in the year 2016 was the number 8 Pharmaceuticals company. Read this report to know the top competitors of Shire and identify growth and cost optimization opportunities of Shire

Mylan (MYL) Business Analysis – Analyze Historical Performance, Strategic Priorities, And...

Mylan N.V. with $11 billion revenues in the year 2016 was the number 9 Pharmaceuticals company. Read this report to know the top competitors of Mylan and identify growth and cost optimization opportunities of Mylan

Valeant Pharmaceuticals (VRX) Business Analysis – Analyze Historical Performance, Strategic Priorities,...

Valeant Pharmaceuticals International, Inc. with $10 billion revenues in the year 2016 was the number 10 Pharmaceuticals company. Read this report to know the top competitors of Valeant Pharmaceuticals and identify growth and cost optimization opportunities of Valeant Pharmaceuticals

Revenues Analysis

Allergan (AGN) Revenues And Revenue Growth From 2012 To 2016

This report provides the last five years revenues and revenue growth of Allergan Plc (AGN) from 2012 to 2016. Allergan generated a total of $14.6 billion revenues during 2016. Allergan reported a revenue growth of 14.8% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Allergan (AGN) Revenues And Revenue Growth From 2011 To 2016

This report provides the last six years revenues and revenue growth of Allergan Plc (AGN) from 2011 to 2016. Allergan generated a total of $14.6 billion revenues during 2016. Allergan reported a revenue growth of 14.8% year-over-year during 2016. The revenues and the revenue growth correspond to the fiscal year ending in December.

Allergan (AGN) Revenue Growth Comparison With Industry Growth From 2012 To...

This report provides a comparison of Allergan Plc (AGN) revenue growth with Pharmaceuticals industry growth during the last five years from 2012 to 2016. Allergan reported a revenue growth of 14.8% year-over-year during 2016. The Pharmaceuticals industry growth was 7.7% year-over-year during 2016. Allergan growth was faster than the industry during 2016.

Profit Analysis

Allergan (AGN) Net Profit And Net Margin From 2012 To 2016

This report provides the last five years net profit and net margin of Allergan Plc (AGN) from 2012 to 2016. Allergan reported a total net income of $15 billion during 2016. Allergan generated a total of $14.6 billion revenues during 2016. Allergan net profit margin was 102.8% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Allergan (AGN) Net Profit And Net Margin From 2011 To 2016

This report provides the last six years net profit and net margin of Allergan Plc (AGN) from 2011 to 2016. Allergan reported a total net income of $15 billion during 2016. Allergan generated a total of $14.6 billion revenues during 2016. Allergan net profit margin was 102.8% during 2016. The net profit and the net profit margin correspond to the fiscal year ending in December.

Allergan (AGN) Net Profit Margin Comparison With Industry From 2012 To...

This report provides a comparison of Allergan Plc (AGN) net profit margin with Pharmaceuticals industry net profit margin during the last five years from 2012 to 2016. Allergan reported a net profit margin of 102.8% during 2016. The Pharmaceuticals industry net profit margin was 15.8% during 2016. Allergan was more profitable than the industry during 2016.

Cost & Expenses Analysis

Allergan (AGN) Cost of Sales (COGS) Analysis From 2012 To 2016

This report provides the last five years cost of sales (COGS) analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan spent a total of $1.9 billion on COGS during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan spent 12.8% of its total revenues on COGS during 2016. The cost of sales (COGS) numbers are for the fiscal year ending in December.

Allergan (AGN) Research & Development (R&D) Spending Analysis From 2012 To...

This report provides the last five years research and development (R&D) expenses of Allergan Plc (AGN) from 2012 to 2016. Allergan spent a total of $2.6 billion on research and development (R&D) activities during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan spent 17.7% of its total revenues on R&D activities during 2016. The R&D spending numbers are for the fiscal year ending in December.

Allergan (AGN) Sales, Marketing, General & Administrative (SG&A) Spending Analysis From...

This report provides the last five years sales, marketing, general & administrative (SG&A) expenses of Allergan Plc (AGN) from 2012 to 2016. Allergan spent a total of $4.7 billion on sales, marketing, general, and administrative (SG&A) activities during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan spent 32.5% of its total revenues on SG&A activities during 2016. The SG&A spending numbers are for the fiscal year ending in December.

Working Capital Analysis

Allergan (AGN) Inventory Spending Analysis From 2012 To 2016

This report provides the last five years inventory spending analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan invested a total of $718 million on inventories during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan invested 4.9% of its total revenues on inventories during 2016. The inventory numbers are for the fiscal year ending in December.

Allergan (AGN) Accounts Receivable (A/R) Analysis From 2012 To 2016

This report provides the last five years Accounts Receivable (A/R) analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan invested a total of $2.5 billion on accounts receivable during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan invested 17.4% of its total revenues on accounts receivable during 2016. The accounts receivable numbers are for the fiscal year ending in December.

Allergan (AGN) Accounts Payable (A/P) Analysis From 2012 To 2016

This report provides the last five years Accounts Payable (A/P) analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan invested a total of $5 billion on accounts payable during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan invested 34.4% of its total revenues on accounts payable activities during 2016. The accounts payable numbers are for the fiscal year ending in December.

Asset Management Analysis

Allergan (AGN) Property, Plant & Equipment (PP&E) Investment Analysis From 2012...

This report provides the last five years property, plant & equipment (PP&E) investment analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan invested a total of $1.6 billion on property, plant & equipment (PP&E) activities during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan invested 11.1% of its total revenues on PP&E activities during 2016. The PP&E investment numbers are for the fiscal year ending in December.

Allergan (AGN) Intangible Assets Analysis From 2012 To 2016

This report provides the last five years Intangible assets analysis of Allergan Plc (AGN) from 2012 to 2016. Allergan invested a total of $109 billion on Intangible assets during 2016. Allergan generated a total of $14.6 billion revenues during 2016. As a percentage of revenues, Allergan invested 747.9% of its total revenues on intangible assets during 2016. The Intangible asset numbers are for the fiscal year ending in December.

Got Questions?

Get in touch with us. We are happy to help!

Contact Us:


sales@revenuesandprofits.com